Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds

Funded Grants

Back to results

Drug Delivery across the Human Blood-Brain Barrier

Project Overview

Toxic amyloid proteins are known to be a significant contributing factor in the development of Alzheimer’s disease. Abnormal clusters of protein fragments build up between nerve cells in the brainleading to impaired memory. The most important therapies in development currently are biologics, antibodies and peptides that bind and neutralize toxic amyloid. However, delivering sufficient quantities of a safe and effective amyloid-targeting biologic across the blood-brain barrier in humans has not yet been possible. KalGene Pharmaceuticals is developing an Alzheimer’s disease therapy based on a naturally-occurring agent that binds specifically to toxic amyloid-beta. When coupled with a blood-brain-barrier carrier molecule developed at the National Research Council of Canada, the compound has been successfully delivered into the brain in Alzheimer’s disease models. KalGene’s project with the Montreal Neurological Institute and the Centre for Imaging Technology Commercialization will proceed to demonstrate this technology in human Alzheimer’s disease patients. An effective Alzheimer’s treatment would have profound personal impact for millions of people and their caregivers worldwide, and would transform the trajectory of healthcare costs. Alzheimer’s disease is one of the most feared health diagnoses. An approach to mitigate the progression of Alzheimer’s disease would bring hope to patients, families and individuals at high risk. The total economic burden of dementia care in Canada alone is expected to rise from $14 billion in 2008 to $75 billion in 2028 with more than half of that attributable to Alzheimer’s disease. This project will also accelerate therapies for other brain conditions beyond Alzheimer’s disease. The difficulty of delivering drugs across the blood-brain barrier has profoundly limited the development of effective therapies for diseases such as brain cancers and Parkinson’s disease. By demonstrating that the blood-brain-barrier carrier technology is effective in delivering an Alzheimer’s therapy in humans, the project will provide a path to develop brain-penetrant therapeutics for other neurological diseases.

Content from CQDM: https://www.cqdm.org/en/projects-portfolio/project/42

Principal Investigator

Nathan Yoganathan , KalGene Pharmaceuticals Inc

Team Members

Louis Collins, McGill University

Jean-Paul Soucy, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University

Danica Stanimirovic, National Research Council of Canada

Balu Chakravarthy, Carleton University

Pedro Rosa-Neto, Douglas Mental Health University Institute

Partners and Donors

CQDM

Ontario Brain Institute

Project Complete

Drug Delivery across the Human Blood-Brain Barrier

  • Grant Type

    Platform grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $1,496,800

  • Health Canada Contribution

    $637,505

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Please note all online donations will receive an electronic tax receipt, issued by Brain Canada Foundation.

Our Donors

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2025 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co